Literature DB >> 19442754

Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER.

Eric R Prossnitz1, Matthias Barton.   

Abstract

GPR30, now named GPER1 (G protein-coupled estrogen receptor1) or GPER here, was first identified as an orphan 7-transmembrane G protein-coupled receptor by multiple laboratories using either homology cloning or differential expression and subsequently shown to be required for estrogen-mediated signaling in certain cancer cells. The actions of estrogen are extensive in the body and are thought to be mediated predominantly by classical nuclear estrogen receptors that act as transcription factors/regulators. Nevertheless, certain aspects of estrogen function remain incompatible with the generally accepted mechanisms of classical estrogen receptor action. Many recent studies have revealed that GPER contributes to some of the actions of estrogen, including rapid signaling events and rapid transcriptional activation. With the introduction of GPER-selective ligands and GPER knockout mice, the functions of GPER are becoming more clearly defined. In many cases, there appears to be a complex interplay between the two receptor systems, suggesting that estrogen-mediated physiological responses may be mediated by either receptor or a combination of both receptor types, with important medical implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442754      PMCID: PMC2740807          DOI: 10.1016/j.prostaglandins.2009.05.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  99 in total

1.  Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors.

Authors:  Zeynep Madak-Erdogan; Karen J Kieser; Sung Hoon Kim; Barry Komm; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2008-07-10

2.  The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.

Authors:  Adele Vivacqua; Daniela Bonofiglio; Anna Grazia Recchia; Anna Maria Musti; Didier Picard; Sebastiano Andò; Marcello Maggiolini
Journal:  Mol Endocrinol       Date:  2005-10-20

3.  The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha.

Authors:  Magdalena Polanczyk; Alex Zamora; Sandhya Subramanian; Agata Matejuk; David L Hess; Elizabeth P Blankenhorn; Cory Teuscher; Arthur A Vandenbark; Halina Offner
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

4.  Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice.

Authors:  Jörg Isensee; Luca Meoli; Valeria Zazzu; Christoph Nabzdyk; Henning Witt; Dian Soewarto; Karin Effertz; Helmut Fuchs; Valérie Gailus-Durner; Dirk Busch; Thure Adler; Martin Hrabé de Angelis; Markus Irgang; Christiane Otto; Patricia Ruiz Noppinger
Journal:  Endocrinology       Date:  2008-12-18       Impact factor: 4.736

Review 5.  Raloxifene use in clinical practice: efficacy and safety.

Authors:  Steven R Goldstein; Claire S Duvernoy; Joaquim Calaf; Jonathan D Adachi; John L Mershon; Sherie A Dowsett; Donato Agnusdei; Cynthia A Stuenkel
Journal:  Menopause       Date:  2009 Mar-Apr       Impact factor: 2.953

6.  Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice.

Authors:  Ulrika E A Mårtensson; S Albert Salehi; Sara Windahl; Maria F Gomez; Karl Swärd; Joanna Daszkiewicz-Nilsson; Anna Wendt; Niklas Andersson; Per Hellstrand; Per-Olof Grände; Christer Owman; Clifford J Rosen; Martin L Adamo; Ingmar Lundquist; Patrik Rorsman; Bengt-Olof Nilsson; Claes Ohlsson; Björn Olde; L M Fredrik Leeb-Lundberg
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

7.  Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Authors:  Peter Collins; Lori Mosca; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Messan G Amewou-Atisso; Mark B Effron; Sherie A Dowsett; Elizabeth Barrett-Connor; Nanette K Wenger
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

8.  The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation.

Authors:  Jian Teng; Zun-Yi Wang; Eric R Prossnitz; Dale E Bjorling
Journal:  Endocrinology       Date:  2008-05-08       Impact factor: 4.736

9.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

10.  The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Authors:  Wen-Hung Kuo; Li-Yun Chang; Daisy Li-Yu Liu; Hsiao-Lin Hwa; Jen-Jen Lin; Po-Huang Lee; Chiung-Nien Chen; Huang-Chun Lien; Ray-Hwang Yuan; Chia-Tung Shun; King-Jen Chang; Fon-Jou Hsieh
Journal:  Taiwan J Obstet Gynecol       Date:  2007-06       Impact factor: 1.705

View more
  49 in total

Review 1.  Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors.

Authors:  M R Meyer; D J Clegg; E R Prossnitz; M Barton
Journal:  Acta Physiol (Oxf)       Date:  2011-02-01       Impact factor: 6.311

2.  Evaluation of estrogen and G protein-coupled estrogen receptor 1 (GPER) levels in drug-naïve patients with attention deficit hyperactivity disorder (ADHD).

Authors:  Nilfer Sahin; Hatice Altun; Ergül Belge Kurutaş; Ebru Fındıklı
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

3.  G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30.

Authors:  Yu Liu; Fei-Ya Du; Wei Chen; Pei-Fen Fu; Min-Ya Yao; Shu-Sen Zheng
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

4.  Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism.

Authors:  Ramy Abdelhamid; Jia Luo; Lawren Vandevrede; Indraneel Kundu; Bradley Michalsen; Vladislav A Litosh; Isaac T Schiefer; Teshome Gherezghiher; Ping Yao; Zhihui Qin; Gregory R J Thatcher
Journal:  ACS Chem Neurosci       Date:  2011-05-18       Impact factor: 4.418

Review 5.  Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives.

Authors:  Matthias Barton; Edward J Filardo; Stephen J Lolait; Peter Thomas; Marcello Maggiolini; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-25       Impact factor: 4.292

6.  The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Authors:  Eric A Ariazi; Eugen Brailoiu; Smitha Yerrum; Heather A Shupp; Michael J Slifker; Heather E Cunliffe; Michael A Black; Anne L Donato; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz; Nae J Dun; V Craig Jordan
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

7.  Combinations of physiologic estrogens with xenoestrogens alter calcium and kinase responses, prolactin release, and membrane estrogen receptor trafficking in rat pituitary cells.

Authors:  Yow-Jiun Jeng; Mikhail Kochukov; Cheryl S Watson
Journal:  Environ Health       Date:  2010-10-15       Impact factor: 5.984

8.  GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011

Review 9.  G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis.

Authors:  Haifei Shi; Shiva Priya Dharshan Senthil Kumar; Xian Liu
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

10.  Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats.

Authors:  Diane Lebesgue; Michael Traub; Maxine De Butte-Smith; Christopher Chen; R Suzanne Zukin; Martin J Kelly; Anne M Etgen
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.